Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 217

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 6
Chunk 217
---
 Innate Pharma's activities in order to (i) take into account the outperformance inherent to a fast-growing biotech company and (ii) motivate the executives to exceed their objectives.

The strategic pillars are the following: (i) partnering Lacutamab, (ii) completing IPH6501 dose level 3, (iii) IND filing by 3Q2024 for IPH4502, complemented by two other pillars: (iv) finance and (v) corporate.

Each pillar was subdivided into:

(i) core objectives; and

(ii) outperformance targets.

The weights of each pillar are as follows:

If 100% of the core objectives are achieved, 100% of the corresponding bonus is paid. If not 100% of the core objectives is achieved, the percentage of the bonus paid is proportional to the percentage of achievement of the core objectives. In case of outperformance for the year 2024, it may be decided to increase the amount of the bonus beyond 100% up to a limit of 150% based on other predefined criteria.

The outperformance targets may only be reached if 100% of the core objectives are reached.

•Performance Free Shares. The members of the Executive Board are able to receive, upon authorization of the Supervisory Board and upon recommendation of the Compensation and Nomination Committee, equity compensation in the form of performance free shares.

• Other Benefits. The members of the Executive Board may also receive other benefits consisting of a supplementary pension plan, in-kind benefits and, for the Chairman of the Executive Board, an unemployment insurance.

Executive Compensation Clawback Policy

Pursuant to the rules adopted by the SEC pursuant to Section 10D-1 of the Exchange Act, requiring national securities exchanges and national securities associations, such as the NYSE, to amend their relevant listing standards no later than November 28, 2023 to require companies with listed securities to put in place a policy whereby listed companies will recover erroneously-awarded variable compensation from the Chief Executive Officer and certain other “executive officers” as defined in Rule 10D-1(d) under the Exchange Act. On June 9, 2023, the SEC approved the Nasdaq’s proposed rule amending its listing standards for recovery of erroneously awarded compensation by listed issuers, which has taken effect on October 2, 2023.

On October 13, 2023, the Supervisory Board approved the adoption of a clawback policy, applicable from October 2,